In an interview to CNBC-TV18, Rajesh Agrawal, CFO of Gulshan Polyols spoke about the latest happenings in the company and his outlook going ahead.
Sun Pharma CFO Uday Baldota said given the complexity of the merger, it is difficult to give guidance for FY16, adding that the company is undertaking remediation plans for all Ranbaxy facilities.
With Sun Pharma-Ranbaxy merger complete, Sun is now India's largest and the world's fifth largest drug maker with combined revenue of USD 5.14 billion
The company has 20 facilities across the globe with portfolio of more than 200 products in 138 countries.
The company has grown faster than the market in India and would be focused on research and development (R&D) spends going forward, said Uday Baldota, CFO, Sun Pharma.
As 2014 comes to an end, Surajit Pal of Prabhudas Lilladher shares his outlook on the year that was and the possible trends for 2015.
In an interview to CNBC-TV18, Ashok Chawla, Chairperson, CCI, said the order on Sun-Ranbaxy merger is final and that the companies could be given additional 4 months in case the product divestment process exceeds 6 months.
The pharma major is hopeful of maintaining its revenue growth guidance of 13-15 percent for FY15 though the margins may get impacted marginally.
Ranbaxy has first-to-file status, meaning eligibility for six months of generic sales exclusivity for both AstraZeneca's heartburn drug Nexium & Roche's antiviral drug Valcyte drugs. However, the final approvals for these drugs were delayed because of the compliance issues at Ranbaxy's plants.
If a ban is imposed on the cholestoral drug, then Ranbaxy is likely to lose Rs 76 crore in revenues.
Drug-maker Wockhardt has fallen foul of the US drug regulator once again and this time, the focus is on its Chikalthana plant.
The question that needs to be resolved is what exactly is happening in terms of product filing and why is Ranbaxy saying that the product filings have not been impacted, says Vikas Dandekar, India Bureau Chief, PharmAsiaNews.Com.
Given the fact that US gets 35 percent of its drugs from India, the regulator is only doing its job in looking closely at not just India's, but other countries‘ pharma units too, adds Ramesh Adige, former executive director, Ranbaxy.
Ajay Piramal says that Indian growth will be higher than the rest of the world soon and adds that the financial services sector is ripe for investment with lucrative returns on offer.
Arun Sawhney, managing director and chief executive officer, Ranbaxy continues to deny any wrong doing. He says the USFDA's ban on its products is due to different definitions of what is 'adulterated' in the US and in India.
Agreeing to past misdeeds, Ranbaxy Laboratories says that the company is taking measure to set things right but cliams to be unaware of DCGI probe.
Ranbaxy shares declined a further 2 percent on Wednesday morning after a media report said a prominent hospital in Mumbai had advised doctors to stop using the pharma company's drugs.
Ranbaxy managing director and chief executive Arun Sawhney told CNBC-TV18 that the pharmaceutical company would end fiscal 2012 with better sales and profits
Vikas Dandekar of PharmAsiaNews.com tells CNBC-TV18 that the US FDA approval for Lipitor is definitely going to be a big positive for Ranbaxy.
Chirag Talati, pharma analyst at Espirito Santo Securities tells CNBC-TV18 that Ranbaxy is most likely set to go ahead with the launch of the generic version of Lipitor, but how much market share it commands needs to be watched.
The US Foods and Drugs Administration (USFDA) will be sued by the US pharmaceutical company Mylan Inc, for an injunction on the launch of Ranbaxy’s cholesterol treatment drug Aricept, which is a generic version of Pfizer’s Lipitor.
Ranbaxy CFO, Omesh Sethi has resigned. PharmAsia News India Bureau Chief, Vikas Dandekar, speaks exclusively to CNBC-TV18’s Reema Tendulkar on the exit and what it means for Ranbaxy.
Kamal Sharma, Managing Director of Lupin, started four decades ago almost as a stockiest and C&F agent. Today, his company is one of India’s largest drug manufacturers and the 5th largest generic drug manufacturer in the world.
Drug majors Ranbaxy and Merck have called off a deal that would have seen both the pharma giants join hands to research anti-infectives, reports PharmAsia News. The deal between the two companies was struck in 2008. Ranbaxy was to get milestones and an undisclosed upfront fee as part of the deal.